Bausch + lomb receives health canada approval of lumify® redness reliever eye drops

Lumify® is canada's first and only over-the-counter eye drop with low-dose brimonidine for the relief of eye redness vaughan, on , may 24, 2022 /prnewswire/ -- bausch + lomb corporation (nyse/tsx: blco) ("bausch + lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that health canada has approved lumify® (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over-the-counter (otc) eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults.1 "with health canada's approval of lumify®, we are excited to be able to now offer canadians a new option to help relieve their red, irritated eyes," said joe gordon, president, global consumer, surgical and vision care. "bausch + lomb is dedicated to meeting the needs of eye care professionals and their patients, and we're proud to bring lumify® forward as an example of our continued commitment to developing innovative eye health products.
BLCO Ratings Summary
BLCO Quant Ranking